First-time prescribing rates of AOM semaglutide increased in early 2024 and then have remained relatively stable and flat
Following a review completed in 2024, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that available evidence did not support a causal link between GLP-1 receptor agonists and suicidal ideation or self-harm, a conclusion also reflected in MHRA communications that year
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, et al
Can Ozempic cause gallstones
Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, et al
Now we now that after one year we can go on a fortnight injection, or switch to oral ones